Drug discovery collaboration will leverage both companies’ botanical drug development expertise
VANCOUVER, BC, June 9, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) and Jaguar Health, Inc. (NASDAQ: JAGX) today announced that the companies have signed a letter of intent to enter into an agreement to collaborate to develop drugs prescription botanicals for specific indications of psychoactive targets in United States. The objective of the collaboration is to extend the botanical drug development capabilities of both companies to develop standardized pharmaceutical-grade drug candidates and to partner with a potential future licensee regarding the development and commercialization of these new herbal medicines for indications such as attention deficit/hyperactivity disorder (ADHD) and social anxiety disorder.
“We are excited about this collaboration with Filament Health, a company focused on the discovery, development and standardization of botanical medicines as well as delivery to patients with mental health issues,” said Steven King, PhD, Jaguar’s Head of Sustainable Sourcing, Head of Ethnobotanical Research and Intellectual Property, and Head of the Company’s Entheogen Therapeutics (ETI) Initiative. Jaguar’s ETI aims to discover and develop breakthrough, innovative and natural medicines derived from psychedelic and psychoactive plants for the treatment of mood disorders, neurodegenerative diseases, addiction and mental health disorders. “Jaguar and Filament are identifying plant candidates that may prove beneficial in treating indications such as ADHD and social anxiety disorder, for which we plan to work collaboratively to develop botanical medicines.”
“Filament is a leader in the development of botanical medicines, and we are committed to supporting the treatment of mental health conditions through our expertise and technology,” said Benjamin Lightburn, CEO of Filament Health. “We have developed new manufacturing and standardization techniques which we have applied to psilocybin, psilocin and ayahuasca. We are delighted to partner with Jaguar and look forward to working with their team to identify and standardize new entheogens.
Under the partnership, Jaguar will be responsible for the identification of plants that may offer novel mechanisms of action, as well as the development of botanical drugs and the raw material supply chain. Filament will be responsible for developing the manufacturing techniques needed to produce standardized pharmaceutical-grade drug candidates. The two companies will then jointly seek a partnership with a potential licensee for the full development and commercialization of new drug candidates, with proceeds from the relationship split equally between Jaguar and Filament.
“We very much look forward to working with Filament on this initiative,” said Lisa Conte, Chairman, CEO and Founder of Jaguar. “Jaguar’s core team began focusing more than 30 years ago on the development and commercialization of herbal prescription medicines, and our Mytesi® (crofelemer), approved by the US FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, is the only oral herbal prescription medication approved by the FDA Botanical Guidance. Filament’s expertise in natural product chemistry and drug development leverages a key asset we’ve generated over 30 years – a library of 2,300 medicinal plants and 3,500 plant extracts, all derived from a survey first-hand ethnobotany by Jaguar and our ETI Science Strategy Team (SST).”
The ETI SST will support this collaboration and is composed of world-renowned ethnobotanists, physicians and pharmacologists, as well as experts in the fields of natural product chemistry and neuropharmacology:
- Michael J. Balickdoctorate: Considered one of the greatest ethnobotanists and economic botanists in the world; specialist in medicinal plants and poisonous plants and their use by indigenous peoples; research associate of the Brain Chemistry Labs of the Institute of Ethnomedicine; member of the original science strategy team that helped develop Jaguar’s plant library.
- Thomas CarlsonMD, MS: Ethnobotanist, botanist, physician; professor of integrative biology at University of California, Berkeley; member of the original science strategy team that helped develop the Jaguar Plant Library; key architect of the ethnomedical field research process conducted by ethnobotanist/physician teams from Jaguar’s predecessor company, Shaman Pharmaceuticals.
- Pravin Chaturvedidoctorate: Pharmacologist with specialty in neuropharmacology; Chairman of the Scientific Advisory Board of Napo Pharmaceuticals (Napo), a wholly owned subsidiary of Jaguar, and Chief Scientific Officer of Jaguar; Over 25-year career, led discovery and/or development activities for several new chemical entities, including the development of Napo’s FDA-approved drug, Mytesi® (crofelemer), the only oral herbal medicine approved by the FDA Botanical Guidance.
- Julie Anne Chinnock, ND, MPH, ARNP/CRNA: ethnobotanist; doctor of naturopathic medicine; owner and manager of Ketamine Clinic; member of the original Shaman Pharmaceuticals field research teams; public health specialist.
- Stephen DahmerMD: Researcher in ethnomedicine and practicing integrative physician; endocannabinoid expert who has conducted ethnomedical field research in tropical regions.
- Wade Davisdoctorate: Ethnobotanist, anthropologist, writer and professor of anthropology at University of British Columbia; extensive international ethnobotanical field research.
- Elaine Elisabetsky, Ph.D.: Among the best ethnopharmacologists in the world; professor in the departments of pharmacology and biochemistry of the Universidade Federal do Rio Grande do Sul in Brazil; member of the original science strategy team that helped develop Jaguar’s plant library.
- Nigel GerickeMBBCh. : Physician, ethnobotanist and ethnopharmacologist; former member of the United States Pharmacopoeia Advisory Board; long-time member of the World Wide Fund for Nature’s Medicinal Plants Specialist Group; founding member of the Association for African Standards of Medicinal Plants.
- Maurice Iwudoctorate: Chairman of the Bioresources Development Group and founder of the International Center for Ethnomedicine and Drug Development (InterCEDD) in Nigeria; member of the original science strategy team that helped develop Jaguar’s plant library.
- Steven R. Kingdoctorate: ethnobotanist; Napo Sustainable Sourcing and Ethnobotanical Research Manager; managed Napo’s original science strategy team and its results; associate researcher at the Brain Chemistry Labs of the Institute of Ethnomedecine.
- Charles LimbachMD: Ethnomedical specialist and family physician; member of the original science strategy team that helped develop Jaguar’s plant library.
- David Sesindoctorate: Natural products chemist; manufacturing director of Jaguar; created an insulation and manufacturing process for Mytesi (crofelemer).
About Filament Health
(OTCQB: FLHLF) (NEO: FH) (FSE: 7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived botanical medicines can improve the lives of many people, with a mission to get them into the hands of everyone who needs them as soon as possible. Filament’s proprietary intellectual property platform enables the discovery, development and delivery of natural medicines, including psychedelic drugs, for clinical development. The filament is leading the way with the very first natural psychedelic drug candidates.
About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals and Napo Therapeutics
Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing novel herbal, non-opioid, and sustainably-derived prescription medicines for people and animals with gastrointestinal disorders, including chronic and debilitating diarrhea. Jaguar Animal Health is a trading name of Jaguar Health. Jaguar Health’s wholly-owned subsidiary, Napo Pharmaceuticals, Inc., is focused on the development and commercialization of proprietary human plant-based pharmaceutical products from plants responsibly harvested from rainforest areas. Our drug candidate crofelemer is the subject of on target study, an ongoing pivotal Phase 3 clinical trial for the prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics SpA (f/k/a Napo EU SpA), an Italian company created by Jaguar Health in Milan, Italy in 2021 which focuses on expanding access to crofelemer in Europe.
Certain statements contained in this press release constitute “forward-looking statements”. These include statements regarding the expectation that the collaboration between Jaguar and Filament will identify candidate herbs that may prove beneficial in treating indications such as ADHD and social anxiety disorder, and the expectation that this collaboration identify and standardize new entheogens. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “expect”, “plan”, “aim”, “anticipate”, ” could”, “intend”, “target”, “project”, “consider”, “believe”, “estimate”, “predict”, “potential”, or “continue” or the negative form of these terms or other similar expressions. The forward-looking statements contained in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections regarding future events. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control.Except as required by applicable law, Jaguar does not does not intend to publicly update or revise the statements forward-looking statements contained herein, whether as a result of new information, future events, changed circumstances or otherwise.
SOURCE Filament Health Corp.
For further information: Jaguar Health: Peter Hodge, Jaguar Health, Inc., [email protected], Jaguar-JAGX; Filament Health: Anna Cordon, Director of Communications, [email protected]